A Clinical Evaluation of the Effects of Combination Photochemotherapy in the Treatment of Psoriasis with Etretinate and PUVA.
- Author:
Yoon Kee PARK
;
Seung Kyung HANN
;
Kyung Tai HONG
- Publication Type:Original Article
- Keywords:
Psoriasis;
Etretinate;
PUVA;
RePUVA
- MeSH:
Acitretin*;
Body Weight;
Cheilitis;
Etretinate*;
Humans;
Membranes;
Photochemotherapy*;
Psoriasis*;
PUVA Therapy
- From:Korean Journal of Dermatology
1987;25(4):460-466
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
RePUVA therapy is the combination of an oral aromatic retinoid(etretinate) with oral photochemotherapy (PUVA) for the treatment of psoriasis. This combination therapy has the advantage of faster clearance with fewer side effects. Twenty three ambulatory psoriasis patients received RePUVA treatment. Etretinate was administered in a dosage of approxirnately 0.75 mg/kg body weight for 2 weeks and discontinued. One week after discontinuance of etretinate, PUVA therapy was begun. Complete clearance occured in 96% of the patients with an average of 9.5+4 irradiations and an accumulated ultraviolet A (UVA) dose of 67.5+42 J/cm. The primary side effects were dry rnucous membranes and mild cheilitis. Laboratory findings revealed no significant abnormalities before or after etretinate treatment.
